NPH-101
Major Depressive Disorder (MDD)
Key Facts
About Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to addressing the significant unmet medical needs in psychiatry and neurology by advancing a pipeline of innovative CNS therapeutics. Its lead candidate, NPH-101, is a novel rapid-acting antidepressant in Phase 2 development for major depressive disorder. The company's strategy is built on a deep understanding of neurocircuitry and a platform designed to identify compounds with superior efficacy and tolerability compared to existing treatments.
View full company profileAbout Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to addressing the significant unmet medical needs in psychiatry and neurology by advancing a pipeline of innovative CNS therapeutics. Its lead candidate, NPH-101, is a novel rapid-acting antidepressant in Phase 2 development for major depressive disorder. The company's strategy is built on a deep understanding of neurocircuitry and a platform designed to identify compounds with superior efficacy and tolerability compared to existing treatments.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| XEN1101 | Xenon Pharmaceuticals | Phase 3 |
| BHV-5000 (NMDA antagonist) | Biohaven | Phase 1 |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| Navacaprant (NMRA-140) | Neumora Therapeutics | Phase 3 |
| MW-101 | MindWalk Holdings | Phase 2 |
| Itruvone (PH10) | Vistagen Therapeutics | Phase 2 |